Posts
News
Latest
Hot
$Esperion Therapeutics (ESPR.US)$
Event-Driven Research Note
Ticker: ESPR
Time Stamp: February 13, 2026 – 4:25 PM ET
Catalyst Window: Week of February 17, 2026
Event: Anticipated U.S. Dyslipidemia Guideline Update
ESPR – High-Conviction Catalyst Setup Into Guideline Inclusion
As of 4:15 PM ET, February 13, we view Esperion Therapeutics (ESPR) as the most asymmetric near-term catalyst opportunity in SMID-cap bio...
Event-Driven Research Note
Ticker: ESPR
Time Stamp: February 13, 2026 – 4:25 PM ET
Catalyst Window: Week of February 17, 2026
Event: Anticipated U.S. Dyslipidemia Guideline Update
ESPR – High-Conviction Catalyst Setup Into Guideline Inclusion
As of 4:15 PM ET, February 13, we view Esperion Therapeutics (ESPR) as the most asymmetric near-term catalyst opportunity in SMID-cap bio...
3
$Hims & Hers Health (HIMS.US)$
I can give you **realistic expected price *ranges* for Hims & Hers (HIMS) from now through **2030**, but first a few important notes so the range is *useful* and not misleading:
### ⚠️ A price range is *not* a precise forecast
It’s a conditional estimate based on:
✔ Fundamental trajectory
✔ Macro outlook
✔ Sector trends
✔ Volatility behavior
✔ Scenario modeling (Bull / Base / Bear)
I **cannot promise exact numbers** — only reasonable projected bands under differe...
I can give you **realistic expected price *ranges* for Hims & Hers (HIMS) from now through **2030**, but first a few important notes so the range is *useful* and not misleading:
### ⚠️ A price range is *not* a precise forecast
It’s a conditional estimate based on:
✔ Fundamental trajectory
✔ Macro outlook
✔ Sector trends
✔ Volatility behavior
✔ Scenario modeling (Bull / Base / Bear)
I **cannot promise exact numbers** — only reasonable projected bands under differe...
2
3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Medtronic (MDT.US)$ is scheduled to report its fiscal third-quarter 2026 earnings on Tuesday, February 17, 2026, before the market opens.
The company is currently in a "turnaround" phase, shifting from a slow-moving legacy giant to a more innovative, agile competitor. After a strong Q2 beat and raise, the market is looking for evidence that this momentum is sustainable.
Earnings Expectations & Key Metrics
Analysts expect a slig...
The company is currently in a "turnaround" phase, shifting from a slow-moving legacy giant to a more innovative, agile competitor. After a strong Q2 beat and raise, the market is looking for evidence that this momentum is sustainable.
Earnings Expectations & Key Metrics
Analysts expect a slig...
+1
3
1
$Hims & Hers Health (HIMS.US)$
What should I do now? Please advise
What should I do now? Please advise
1
20
$Hims & Hers Health (HIMS.US)$ Hims & Hers Q4 2025 earnings conference call is scheduled for February 23 at 5:00 PM ET/February 24 at 6:00 AM SGT/February 24 at 9:00 AM AEDT. Subscribe to join the live earnings conference with management NOW!
Beat or Miss?
What do you expect from Hims & Hers's Q4 earnings? Will the company beat or miss the estimates? Make sure to click the "Book" button to get what Hims & Hers's management has to say!
Disclaimer:
This...
Beat or Miss?
What do you expect from Hims & Hers's Q4 earnings? Will the company beat or miss the estimates? Make sure to click the "Book" button to get what Hims & Hers's management has to say!
Disclaimer:
This...
Hims & Hers Q4 2025 earnings conference call
Feb 23 16:00
Book 3
$Moderna (MRNA.US)$ is scheduled to report its fiscal Q4 2025 and full-year results on Friday, February 13, 2026, at 8:00 a.m. ET.
The company is currently in a high-stakes transition from a pandemic-focused entity to a diversified biotech platform. While recent "pre-announcements" in January have already shared some high-level figures, the official report will be the definitive signal for 2026 sentiment.
Moderna's (MRNA) Fiscal Q3...
The company is currently in a high-stakes transition from a pandemic-focused entity to a diversified biotech platform. While recent "pre-announcements" in January have already shared some high-level figures, the official report will be the definitive signal for 2026 sentiment.
Moderna's (MRNA) Fiscal Q3...
+4
24
1